Teva Announces Exclusive Launch of Generic Pataday® in the United States
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pataday®1 (olopatadine hydrochloride ophthalmic solution) 0.2%, in the U.S. Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis. Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 6